Pacific Biosciences of California (PACB) Stock Forecast & Price Target

$1.97 +0.04 (+2.07%)

(As of 12/20/2024 05:51 PM ET)

Pacific Biosciences of California - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
0

Hold
6

Buy
6

Based on 12 Wall Street analysts who have issued ratings for Pacific Biosciences of California in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 6 have given a hold rating, and 6 have given a buy rating for PACB.

Consensus Price Target

$2.95
49.98% Upside

According to the 12 analysts' twelve-month price targets for Pacific Biosciences of California, the average price target is $2.95. The highest price target for PACB is $6.00, while the lowest price target for PACB is $2.00. The average price target represents a forecasted upside of 49.98% from the current price of $1.97.

Get the Latest News and Ratings for PACB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pacific Biosciences of California and its competitors.

PACB Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)	9 Buy rating(s)
Hold	6 Hold rating(s)	8 Hold rating(s)	7 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$2.95	$3.63	$4.50	$11.73
Forecasted Upside	49.98% Upside	101.39% Upside	158.62% Upside	16.46% Upside
Consensus Rating	Moderate Buy	Hold	Moderate Buy	Moderate Buy

This is the worst sign for the U.S. stock market in 50 years (Ad)

The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"

Click here to see Dan's new, urgent warning about the U.S. market for 2025.

PACB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PACB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pacific Biosciences of California Stock vs. The Competition

Type	Pacific Biosciences of California	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	49.98% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent PACB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
11/11/2024	Scotiabank 5 of 5 stars	Lower Target	Sector Outperform ➝ Sector Outperform	$7.00 ➝ $6.00	+156.41%
11/11/2024	UBS Group 4 of 5 stars	Downgrade	Buy ➝ Neutral	$2.00	-11.11%
11/11/2024	Piper Sandler 2 of 5 stars	Boost Target	Neutral ➝ Neutral	$2.00 ➝ $2.50	+8.70%
8/12/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $2.00	+36.99%
8/8/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$3.50 ➝ $3.50	+135.69%
8/8/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$3.50 ➝ $3.00	+96.08%
This is the worst sign for the U.S. stock market in 50 years (Ad) The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone" Click here to see Dan's new, urgent warning about the U.S. market for 2025.
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00	+113.98%
5/10/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$3.00 ➝ $2.00	+11.97%
4/22/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
4/18/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$9.00 ➝ $2.50	+73.01%
4/18/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$7.00 ➝ $2.50	+78.57%
4/17/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$12.00 ➝ $2.50	+79.86%
12/14/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$11.00	+24.15%
12/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
6/7/2023	KGI Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:15 AM ET.

PACB Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Pacific Biosciences of California is $2.95, with a high forecast of $6.00 and a low forecast of $2.00.
: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PACB shares.
: According to analysts, Pacific Biosciences of California's stock has a predicted upside of 49.98% based on their 12-month stock forecasts.
: Over the previous 90 days, Pacific Biosciences of California's stock had 1 upgrade and 1 downgrade by analysts.
: Pacific Biosciences of California has been rated by research analysts at Piper Sandler, Scotiabank, and UBS Group in the past 90 days.
: Analysts like Pacific Biosciences of California less than other "medical" companies. The consensus rating score for Pacific Biosciences of California is 2.50 while the average consensus rating score for "medical" companies is 2.81. Learn more on how PACB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This is the worst sign for the U.S. stock market in 50 years (Ad)

Click here to see Dan's new, urgent warning about the U.S. market for 2025.

This page (NASDAQ:PACB) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacific Biosciences of California (PACB) Stock Forecast & Price Target